Medical Condition

advanced solid tumors

Total Trials

35

Recruiting Now

35

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumors sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — advanced solid tumors Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumors?

ClinicalMetric currently tracks 35 actively recruiting clinical trials for advanced solid tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 35. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for advanced solid tumors?

advanced solid tumors research spans Phase 1 (32 trials), Phase 2 (10 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a advanced solid tumors clinical trial?

Eligibility criteria for advanced solid tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Eikon Therapeutics 2 trials

Astellas Pharma Global Development, Inc. 1 trial

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 1 trial

Shanghai Hengrui Pharmaceutical Co., Ltd. 1 trial

ModernaTX, Inc. 1 trial

advanced solid tumors

Frequently Asked Questions — advanced solid tumors Clinical Trials

Recruiting Clinical Trials

A Study of ASP1002 in Adults for Treatment of Solid Tumors

SKB445 for Injection in Solid Tumors

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

A Study of BG-C477 in Participants With Advanced Solid Tumors

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

HWS116 Monotherapy in Patients With Advanced Solid Tumors

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

A Study of BGM-2121 in Patients With Advanced Solid Tumors

A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase I Study of HBT-708 for Patients With Advanced Solid Tumors

A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.